Related Experiment Video
Updated: Dec 12, 2025
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Targeting CDK4/6 in mantle cell lymphoma
Christina Lee1,2, Xiangao Huang1, Maurizio Di Liberto1
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Abstract:
Targeting the cell cycle represents a rational approach to mantle cell lymphoma (MCL) therapy, as aberrant expression of cyclin D1 and dysregulation of CDK4 underlie cell cycle progression and proliferation of MCL cells. Although cell cycle cancer therapy was historically ineffective due to a lack of selective and effective drugs, this landscape changed with the advent of selective and potent small-molecule oral CDK4/6 inhibitors. Here, we review the anti-tumor activities and clinical data of selective CDK4/6 inhibitors in MCL. We summarize the known mechanism of action of palbociclib, the most specific CDK4/6 inhibitor to date, and the strategy to leverage this specificity to reprogram MCL for a deeper and more durable clinical response to partner drugs. We also discuss integrative longitudinal functional genomics as a strategy to discover tumor-intrinsic genomic biomarkers and tumor-immune interactions that potentially contribute to the clinical response to palbociclib in combination therapy for MCL. Understanding the genomic basis for targeting CDK4/6 and the mechanisms of action and resistance in MCL may advance personalized therapy for MCL and shed light on drug resistance in other cancers.
Insights
Selective CDK4/6 inhibitors, like palbociclib, show promise for mantle cell lymphoma (MCL) therapy by targeting cell cycle dysregulation. Understanding their genomic basis and resistance mechanisms can advance personalized MCL treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mantle cell lymphoma (MCL) cells exhibit aberrant cyclin D1 expression and CDK4 dysregulation, driving cell cycle progression.
- Historically, cell cycle-targeted cancer therapies lacked selectivity and efficacy.
- The development of selective oral CDK4/6 inhibitors has transformed this therapeutic landscape.
Purpose of the Study:
- To review the anti-tumor activities and clinical data of selective CDK4/6 inhibitors in MCL.
- To summarize the mechanism of action of palbociclib, a specific CDK4/6 inhibitor.
- To explore strategies for enhancing clinical responses to palbociclib in combination therapy for MCL.
Main Methods:
- Review of existing clinical data and anti-tumor activities of CDK4/6 inhibitors in MCL.
- Summary of palbociclib's mechanism of action and specificity.
- Discussion of integrative longitudinal functional genomics for biomarker discovery.
Main Results:
- Selective CDK4/6 inhibitors demonstrate anti-tumor activity in MCL.
- Palbociclib's specificity offers a strategy to improve clinical responses when combined with partner drugs.
- Functional genomics can identify biomarkers and immune interactions influencing treatment response.
Conclusions:
- Targeting CDK4/6 is a rational approach for MCL therapy.
- Understanding the genomic basis and resistance mechanisms of CDK4/6 inhibition is crucial for personalized MCL treatment.
- This research may offer insights into drug resistance in other cancer types.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39Positive Regulator Molecules